OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6896$3.4354

Golden Throat Holdings Group Co Ltd

PharmaceuticalsVerified

Golden Throat Holdings Group Co Ltd has a market capitalization of 2.54 billion CNY, with a market price of 3.43 CNY per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 739.3 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks. The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown is provided, and there is no information on the geographic distribution of its sales. The company's growth trajectory is not quantified in the outlook data. No numeric deltas or forward-looking revenue guidance is available to assess the company's performance in the current or next fiscal year. The company is flagged for liquidity risk due to the absence of balance-sheet inputs and no going-concern language in source documents. No dilution risk is currently present, as the number of basic and diluted shares is the same. No adjustments have been applied to the valuation metrics, and no specific dilution sources are identified in the available data. No recent events, such as filings or transcripts, are available in the source documents to provide insight into the company's recent developments or strategic direction.

30-day price · 6896-0.18 (-4.9%)
Low$3.39High$3.75Close$3.52As of21 May, 00:00 UTC
Profile
CompanyGolden Throat Holdings Group Co Ltd
Ticker6896.HK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Golden Throat Holdings Group Co Ltd is a pharmaceutical company that develops, produces, and sells over-the-counter (OTC) medicines and health products, primarily in the Chinese market.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92.

Golden Throat Holdings Group Co Ltd has a market capitalization of 2.54 billion CNY, with a market price of 3.43 CNY per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 739.3 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry benchmarks. The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown is provided, and there is no information on the geographic distribution of its sales. The company's growth trajectory is not quantified in the outlook data. No numeric deltas or forward-looking revenue guidance is available to assess the company's performance in the current or next fiscal year. The company is flagged for liquidity risk due to the absence of balance-sheet inputs and no going-concern language in source documents. No dilution risk is currently present, as the number of basic and diluted shares is the same. No adjustments have been applied to the valuation metrics, and no specific dilution sources are identified in the available data. No recent events, such as filings or transcripts, are available in the source documents to provide insight into the company's recent developments or strategic direction.
Key takeaways
  • The company has no dilution risk, as basic and diluted shares are equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • No profitability or return metrics are available for comparison to industry benchmarks.
  • No segment or geographic revenue breakdown is disclosed in the available data.
  • No forward-looking growth guidance is available to assess the company's future performance.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$820.5M$244.8M$187.6M$131.2M
FY-3$992.0M$386.3M$281.2M$190.4M
FY-2$961.4M$371.7M$250.2M$28.3M
FY-1$1.19B$452.6M$318.6M-$116.4M
FY0$943.3M$343.2M$251.2M-$99.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.95B$1.37B
FY-3$2.30B$1.54B
FY-2$2.30B$1.55B
FY-1$2.25B$1.47B
FY0$2.29B$1.38B
PeriodOCFCapExFCFSBC
FY-4$164.9M-$56.6M$131.2M
FY-3$271.1M-$15.8M$190.4M
FY-2$238.8M-$17.5M$28.3M
FY-1$475.9M-$67.2M-$116.4M
FY0$123.3M-$45.3M-$99.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price$3.43
Market cap$2.54B
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
Metric6896Activity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 04:18 UTC#7a269ac5
Market quoteclose CNY 3.55 · shares 0.74B diluted
no public URL
2026-05-07 04:18 UTC#11cd26f3
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:26 UTCJob: bbc8020c